This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.
Priya, Radhika Mittal, Jyotirmoy Banerjee et al.· International review of neur...· 0 citations
This chapter addresses the gap and consolidates existing information connecting lipid modifications to metabolic dysfunction in AD, emphasizing molecular pathways and prospective treatment strategies aimed at lipid metabolism to re-establish bioenergetic equilibrium.
Nitin Yadav, Jyotirmoy Banerjee, Manisha Tiwari et al.· International review of neur...· 0 citations
This review comprehensively examines the ACK family architecture, regulation, epigenetic mechanisms, and roles in several malignancies and evaluates targeted therapies, immunotherapy, and drug development including selective inhibitors, dual agents, and rational combinations.
Radhika Mittal, P. Priya, Jyotirmoy Banerjee et al.· Expert opinion on therapeuti...· 0 citations
The chapter outlines the current evidences on dysregulated metabolic processes, and highlights emerging metabolic biomarkers that are identified through advanced neuroimaging modalities, plasma/cerebrospinal fluid (CSF) profiles, lipidomic signatures and markers of mitochondrial impairment, underscoring their diagnosti...
Radhika Mittal, Priya, Jyotirmoy Banerjee et al.· International review of neur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
